Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) just unveiled an announcement.
GenFleet Therapeutics has initiated the first registrational Phase III study of GFH375, an oral KRAS G12D inhibitor, for patients with metastatic pancreatic cancer. This trial marks a significant milestone as it is the world’s first study of its kind, potentially offering a new targeted therapy for a mutation with no approved treatments. The study will enroll approximately 320 patients across 40 sites, aiming to address the poor prognosis associated with pancreatic cancer. The global incidence of this aggressive cancer is projected to rise, highlighting the importance of new therapeutic options. GFH375 has shown promising results in earlier trials and has been granted Fast Track Designation by the U.S. FDA, underscoring its potential impact on the treatment landscape.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a biotechnology company focused on the development of innovative cancer therapies. The company specializes in targeting the RAS/MAPK pathway, with a particular emphasis on KRAS G12D mutations, which are prevalent in pancreatic cancer. GenFleet collaborates with Verastem Oncology to advance its oncology programs, retaining development rights in China while Verastem holds rights outside of China.
Average Trading Volume: 1,698,802
Find detailed analytics on 2595 stock on TipRanks’ Stock Analysis page.